Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1, Multicenter, Open-label, Dose Exploration and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 994 Monotherapy and Combination of AMG 994 and AMG 404 in Subjects With Advanced Solid Tumors
This is a non-randomised trial with two experimental phases. The aim of Phase 1 (Dose Exploration) is to determine the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D) of AMG 994, in combination with AMG 404. Both will be administered via intravenous infusion. In Phase 2 (Dose Expansion), participants will be administered with the MTD or RP2D of AMG 994 identified in the dose escalation part of the study, in combination with AMG 404. Both will be administered via intravenous infusion.